EP1585514A1 - Verfahren zur medikamentösen prophylaxe gegen vergiftungen durch cholinesterase-hemmer, sowie hierfür geeignete wirkstoffe und arzneimittel - Google Patents

Verfahren zur medikamentösen prophylaxe gegen vergiftungen durch cholinesterase-hemmer, sowie hierfür geeignete wirkstoffe und arzneimittel

Info

Publication number
EP1585514A1
EP1585514A1 EP04702672A EP04702672A EP1585514A1 EP 1585514 A1 EP1585514 A1 EP 1585514A1 EP 04702672 A EP04702672 A EP 04702672A EP 04702672 A EP04702672 A EP 04702672A EP 1585514 A1 EP1585514 A1 EP 1585514A1
Authority
EP
European Patent Office
Prior art keywords
active ingredient
ethyl
group
formula
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04702672A
Other languages
German (de)
English (en)
French (fr)
Inventor
Frank Becher
Thomas Hille
Frank Theobald
Aharon Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Israel Institute for Biological Research
Original Assignee
LTS Lohmann Therapie Systeme AG
Israel Institute for Biological Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG, Israel Institute for Biological Research filed Critical LTS Lohmann Therapie Systeme AG
Publication of EP1585514A1 publication Critical patent/EP1585514A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to methods for drug prophylaxis against poisoning, which are caused by cholinesterase inhibitors, in particular those from the class of organophosphorus compounds. It also relates to active substances and medicaments which are suitable as prophylactic agents against such poisoning, in particular medicinal substances with active substances from the group of the phenyl carbamates. The invention further includes the use of the active substances mentioned for the prophylaxis against the poisonings mentioned.
  • Compounds with cholinesterase-inhibiting activity are used on the one hand as insecticides and fungicides in crop protection, on the other hand some of these compounds are suitable for use as warfare agents or combat gases in wars or in terrorist attacks. While the poisoning effect is intended in the latter case, the poisoning of people caused by insecticides or fungicides can be attributed to improper handling, in particular inadequate protective measures during transport or handling.
  • Nerve warfare agents or nerve gases from the class of organic phosphoric acid esters and phosphonic acid esters are the most frequently used poisonous gases.
  • the main representatives of these warfare agents are Tabun (GA), Sarin (GB), Soman (GD) and VX.
  • pesticidal or fungicidally active organophosphates which are used in agriculture or horticulture are parathion (diethyl (4-nitrophenyl) thionophosphate), dimethoate (diethyl1-S-meth 1-carbamoylmethyldithiophosphate) and Called Malathion.
  • Respiratory paralysis is caused. Additional clinical symptoms such as excessive salivation, apnea and seizures appear within the first minutes after exposure to the warfare agent. If not treated adequately and immediately, they can lead to death or permanent damage, comparable to the consequences of irreversible brain damage.
  • Atropine is usually administered parenterally in high doses as an antidote in order to antagonize the acetylcholine effect.
  • autoinjectors which are intended to enable the persons concerned to administer the required dose of atropine themselves in an emergency.
  • such treatment is only promising if it is within one Minute after the poison intake is made. Under the actual circumstances, this is rarely possible because the time available in an emergency (e.g. during combat operations or terrorist attacks) is too short. This is particularly true of the extremely toxic warfare agents Sarin (GB) and Soman (GD).
  • the dose of atropine used for the treatment must be carefully selected depending on the severity of the poisoning, in order to avoid overdosing and atropine poisoning. Realistically, this is hardly possible in practice under operating conditions.
  • organophosphate poisoning by administering oxime compounds (e.g. obidoxime, pralidoxime).
  • oxime compounds e.g. obidoxime, pralidoxime
  • alkyl phosphates e.g. parathion
  • Oximes are effective against most organophosphates, with the exception of e.g. B. Soman (GD).
  • the currently available antidote therapies do not offer adequate protection against seizures due to exposure to neurotoxins and the resulting long-term brain damage and cognitive disorders.
  • DE 43 42 173 A has proposed the use of a combination of physostigmine and scopolamine as a prophylactic measure or for pretreating organophosphate poisoning, this combination being administered by injection or skin patch.
  • the solution according to the invention therefore comprises methods for the prophylactic treatment against poisoning by cholinesterase inhibitors, the methods being based on the administration of (S) -N-ethyl-N-methyl-3- [1- (dimethylaminojethyl] phenylcarbamate or one of these
  • the invention further relates to the use of (S) -N-ethyl-N-methyl-3- [l- (dimethylamino) ethyl] phenylcarbamate, or for prophylaxis against poisoning by cholinesterase inhibitors the invention further comprises pharmaceutical compositions which contain the active ingredient (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenylcarbamate in combination with at least one further pharmaceutical active ingredient.
  • Compound (1) is a carbamic acid ester which inhibits the cholinesterase enzyme by carbamylation. This inhibition is reversible with a half-life of a few minutes. Because of these properties, this active ingredient is used for the therapy of Alzheimer's disease, in which case the acetylcholine deficit caused by the destruction of cholinergic neurons should be compensated for.
  • Compound (1) is approved as a drug for treating Alzheimer's disease and is on the market; it does at least in some patients Improve memory performance. The drug is considered safe; serious side effects are not known.
  • the pharmaceuticals according to the invention for the prophylactic treatment against organophosphate poisoning contain the active ingredient (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenylcarbamate as the free base or in the form of a pharmaceutically acceptable acid addition salt.
  • Particularly suitable salts are: salicylate, hydrogen tartrate, hydrobromide, hydrochloride.
  • the hydrogen tartrate salt of the active ingredient empirical formula C14H22N2O2 • C4H5O6) is particularly suitable, the tartaric acid preferably being in the configuration (2R, 3R).
  • the free active ingredient base or its acid addition salts can be used as racemic mixtures; the (-)-
  • enantiomers of (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenyl carbamate and its acid addition salts are preferred because of their higher selectivity.
  • the direction of rotation can be (+) or (-).
  • the free base (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenyl carbamate can be obtained by amidating ⁇ -m-hydroxyphenylethyl dimethylamine with a corresponding carbamoyl halide.
  • the racemates can be separated and acid addition salts can be prepared by known processes.
  • the R ⁇ radical is selected from the group consisting of hydrogen, unbranched and branched lower alkyl radicals (1 to 5 C atoms), cyclohexyl, allyl and benzyl;
  • R2 is selected from the group consisting of hydrogen, methyl, ethyl and propyl;
  • the rest R3 is selected from the group consisting of hydrogen as well includes unbranched and branched Nißderalkylreste (1 to 5 carbon atoms);
  • the radicals R and R5 are selected from the group of unbranched and branched lower alkyl radicals (1 to 5 carbon atoms), where R4 and R5 can be identical or different; the dialkylaminoalkyl group with the radicals R3, R4 and R5 can optionally be in the ortho, meta or para position.
  • the active compound compounds according to formula (2) can be used as free bases or in the form of their pharmaceutically acceptable acid addition salts.
  • the salts mentioned in connection with compound (1) are particularly suitable, in particular the hydrogen tartrate and the hydrochloride.
  • the compound (1) or one of the compounds of the formula (2), in each case optionally in the form of a pharmaceutically acceptable salt, is administered as a sole active ingredient for the prophylaxis against poisoning by cholinesterase inhibitors to a person at risk.
  • This is a prophylactic measure that is sufficient in itself and does not require any further treatment measures or active ingredients.
  • the compound (1) or one of the compounds of the formula (2) in each case optionally in the form of a pharmaceutically acceptable salt, in combination (ie simultaneously or in succession) with one or more additional active ingredient (s) (s) administered to the person to be treated.
  • the active substance (s) mentioned is / are selected from the group of the parasympatholytic agents, preferably from the group of the tropane alkaloids, with scopolamine is particularly preferred.
  • Other suitable active ingredients from this group are: atropine, butylscopolamine, benzatropine. These active ingredients can also be in the form of their pharmaceutically acceptable salts.
  • compound (1) or an active ingredient according to formula (2) with at least one active ingredient from the group of the parasympatholytics, in particular from the group of the tropane alkaloids, is particularly preferred because these active ingredients are competitive antagonists against released substances
  • the present invention also extends to medicaments which have a content of compound (1) or of an active compound of the formula (2), optionally in the form of a pharmaceutically acceptable salt.
  • medicaments according to the invention which contain such a phenyl carbamate active substance as the sole active substance component are particularly preferred.
  • the medicament used for prophylaxis can contain one or more additional active substance (s), this active substance (s) being selected from the group of the parasympatholytic agents.
  • the medicaments according to the invention which contain compound (1) or at least one compound according to formula (2), can be prepared in various dosage forms using known excipients.
  • pharmaceutical forms are preferably used for enteral or parenteral, in particular transdermal, administration.
  • the active ingredient (s) is / are in an oral enteral dosage form (e.g. tablet, coated tablet, Chewable tablet, lozenge, capsule, powder, suspension, solution) or in a rectal dosage form (e.g. suppository).
  • Suitable formulation auxiliaries are known to the person skilled in the art.
  • Parenteral oral delivery forms such as lozenges, sublingual tablets, sheet-like adhesive systems which are applied to the oral mucosa, sheet-like systems which dissolve on the tongue or the oral cavity and which adhere to the oral mucosa, also come into consideration Apply the active ingredient.
  • devices for administering medicaments to mucosal tissue are also suitable. These devices can be used like a lollipop and essentially comprise a carrier device which is supported on a total mass.
  • the medicaments according to the invention can also be formulated as injection solutions and, for example, contained in a disposable syringe. Depot dosage forms or therapeutic systems which enable delayed and / or controlled release of active ingredient are particularly suitable.
  • antioxidants preferably selected from the group consisting of tocopherol and its derivatives (in particular esters, acetate), ascorbic acid and its derivatives (for example ascorbyl palmitate), butylated hydroxyanisole, butylated hydroxytoluene and Propyl gallate comprises, with tocopherol and As ⁇ orbylpalmi- are particularly preferred. These substances are preferably added in a concentration of 0.01 to approximately 1.0% by weight, preferably 0.05 to 0.5% by weight, in each case based on the entire pharmaceutical preparation.
  • the medicaments according to the invention preferably contain 0.1 to 100 mg, particularly preferably 0.5 to 20 mg of the compound (1) (or an active ingredient according to formula (2)).
  • the active substance content is preferably in the range from 0.1 to 10 mg, in the case of depot pharmaceutical forms or therapeutic systems it is preferably in the range from 1.0 to 100 mg.
  • the content of the further active ingredient (s) (preferably tropane alkaloids) mentioned is preferably in the range from 0.1 to 100 mg, in particular 0.5 to 50 mg.
  • the percentage of active ingredient, based on an individual pharmaceutical preparation is preferably in the range from 0.1 to 50% by weight, in particular in the range from 5 to 40% by weight.
  • the maximum daily dose (based on compound (1)) is approx. 2 6 mg daily (oral) or approx. 24 mg daily (transdermal).
  • the active ingredient is (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenyl carbamate (“compound (1)”), particularly preferably in combination with at least one further active ingredient (especially scopolamine), contained in a flat, film-shaped oral dosage form.
  • These dosage forms which are also known as "wafers", are intended for application in the oral cavity.
  • the medicinal product with its active and ineffective components acquires a gel-like consistency through the entry of saliva - or other liquid - and thus adheres to the mucous membrane. There is the Release of the active ingredients and subsequent absorption through the oral mucosa.
  • the wafer During the release, the wafer remains in the oral cavity, virtually dissolves and releases the active ingredient in a very short time.
  • the wafer is provided with an adhesive layer, so that it adheres to the oral mucosa for a controlled period of time.
  • Wafers essentially contain one or more polymers as basic substances, as well as one or more active ingredient (s) dissolved or dispersed therein.
  • Polymers that are particularly suitable are water-soluble or swellable or decomposable polymers in aqueous media.
  • Polymers selected from the group below are particularly suitable: cellulose derivatives (in particular hydroxypropyl methyl cellulose, carboxy ethyl cellulose, hydroxypropyl cellulose and methyl cellulose); water-soluble polysaccharides that are of vegetable or microbial origin (in particular pullulan, xanthan, alginates, dextrans, pectins, starch); Polyvinyl alcohols, polyacrylates, polyvinyl pyrrolidones; Proteins (preferably gelatin or other gel-forming proteins).
  • cellulose derivatives in particular hydroxypropyl methyl cellulose, carboxy ethyl cellulose, hydroxypropyl cellulose and methyl cellulose
  • water-soluble polysaccharides that are of vegetable or microbial origin in particular pullulan, xanthan, alginates, dextrans, pectins, starch
  • Proteins preferably gelatin or other gel-
  • the wafers mentioned can contain one or more additives selected from the group of
  • Plasticizers dyes and pigments, antioxidants, decay promoters, wetting agents, substances that promote absorption or permeation, pH regulators, fillers, flavors and aromas and sweeteners.
  • Suitable pharmaceutically compatible substances for this purpose are known to the person skilled in the art, as are processes for the production of such wafers (see, for example, DE-A-196 52 268; DE-A-100 32 456; WO-A-98 26 763).
  • a dispersion or solution of the constituents (polymer (s), active ingredient (s), additive (s)) is generally first prepared and this then coated on a flat, inert support and dried.
  • the thickness of these film-like dosage forms is preferably between 0.1 to 5 mm, particularly preferably between 0.5 to 1 mm.
  • the active ingredient or, particularly preferably, an active ingredient combination as described above is contained in a transdermal therapeutic system (TTS). Since the skin permeability of the compound (1) (as a free base or as an acid addition salt), as well as that z. B. of scopolamine, these substances are suitable for the transdermal route of administration.
  • TTS transdermal therapeutic system
  • Transdermal dosage forms are particularly advantageous for the prophylactic use of phenyl carbamate active substances according to the present invention, since they allow precise control of the active substance release over a longer period (up to 72 h), with the result that the dosage interval can be extended. In this way, a plasma concentration sufficient for the desired prophylactic effect can be maintained without unfavorable plasma peak values or fluctuations in the plasma concentration occurring. Therefore, transdermal administration is also much cheaper in terms of side effects; when compound (1) is administered orally, nausea may occur in the treated persons in individual cases. The risk of an overdose is largely excluded at TTS; In addition, an improved acceptance among the people to be treated can be expected.
  • TTS transdermal therapeutic systems
  • a drug reservoir which can either be a membrane-enclosed, bag-shaped reservoir or a polymer-based reservoir ("matrix system"); the latter type is preferred.
  • the reservoir is usually with a carrier layer (for example plastic film, such as
  • PETP PETP, PE; z. B. 10-15 ⁇ thickness
  • the surface of the drug reservoir facing the skin can be covered with a removable protective film (e.g. P z or PETP film, siliconized or fluorosiliconized; e.g. 50-250 ⁇ m thick) before application.
  • a removable protective film e.g. P z or PETP film, siliconized or fluorosiliconized; e.g. 50-250 ⁇ m thick
  • Polymers from the following groups are particularly suitable as polymers for producing the active substance reservoir:
  • Polyacrylates poly (meth) acrylates, polyacrylic acid, cellulose derivatives, especially methyl and ethyl celluloses, isobutylene, ethylene-vinyl acetate, natural and synthetic rubbers such as styrene-diene copolymers, styrene-butadiene block copolymers, isoprene -Block copolymers, acrylonitrile butadiene rubber, butyl rubber or neoprene rubber, silicone pressure sensitive adhesive and hot melt adhesive.
  • Suitable pressure sensitive adhesives are known to the person skilled in the art (e.g. amine-resistant
  • Silicone pressure sensitive adhesives such as B. BIO-PSA® pressure sensitive adhesive, especially 7-4302; Dow Corning). Suitable mixtures of the polymers mentioned can also advantageously be used.
  • hot melt adhesive includes all adhesives that are not liquefied by solvents but by melting at elevated temperatures, for example in the range of 60-200 ° C. As hot melt adhesive z.
  • the active substance reservoir of the TTS according to the invention can also contain various auxiliaries or additives, for example from the group of solubilizers, solvents, plasticizers, tackifiers, permeation improvers, pH regulators, antioxidants and preservatives.
  • the polymer matrix of the active substance reservoir can have one or more layers; it preferably has pressure-sensitive adhesive properties, as a result of which permanent contact of the active substance-dispensing side of the reservoir with the skin is made possible.
  • a separate active substance-free pressure-sensitive adhesive layer or a pressure-sensitive adhesive zone can be provided if the active substance reservoir has no or insufficient pressure-sensitive adhesive properties.
  • the typical structure of a TTS comprises: a backing layer; (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenyl carbamate (as base or as hydrogen tartra) in an acrylate copolymer as the drug reservoir; Silicone pressure sensitive adhesive layer (BIO-PSA® Q7- 4302); removable protective layer.
  • plasticizers skin-compatible surfactants; Polyoxyethylene fatty alcohol ether, preferably with Ci2 ⁇ c 18 ⁇
  • Alcohol particularly preferably polyoxyethylene (10) oleyl ether, in particular Brij® 97 (Atlas Chemie); Polyoxyethylene sorbitol fatty acid esters, preferably with particularly preferred polyoxyethylene (20) sorbitan monooleate (e.g. Tween® 80; Atlas Chemie); Polyoxyethylene- (5-40) -
  • Stearic acid esters e.g. Myrj®; Atlas Chemie
  • Polyoxyethylene glycol fatty alcohol ether e.g. B. polyethylene glycol (6-25) cetyl ether, glycerin polyethylene ricinoleate; glycerol Polyethylene glycol stearate (Cre ophor®; BASF); Polyoxyethylene glycols in the molecular weight range from 200 to 600
  • Dalton Dalton; Cetiol® HE (from Henkel); Lower alkyl esters of adipic acid, especially di-n-butyl adipate, diisopropyl adipate; Glyerine polyethylene glycol ricinoleate (e.g. Cremophor EL, BASF®); Triacetin- (1,2,3); Fatty acids, fatty alcohols, preferably C12-C18.
  • Cetiol® HE from Henkel
  • Lower alkyl esters of adipic acid especially di-n-butyl adipate, diisopropyl adipate
  • Glyerine polyethylene glycol ricinoleate e.g. Cremophor EL, BASF®
  • Triacetin- (1,2,3) Triacetin- (1,2,3)
  • Fatty acids fatty alcohols, preferably C12-C18.
  • Azon l-dodecylazacycloheptan-2-one
  • DE ⁇ T N, N-diethyl-m-toluamide
  • the total proportion of plasticizers and permeation-improving substances can be up to approximately 50% by weight, based on the active substance-containing polymer preparation (active substance reservoir). A content of less than 1% by weight or the complete absence of such additives is particularly preferred.
  • the preparation of the TTS according to the invention can be carried out in such a way that compound (1) and / or an active compound of the formula (2), and optionally further active compounds, are / are coarsely, colloidally or molecularly dispersed in a solution of matrix base polymers and the mixture on a suitable base, for example a plastic film provided with a silicone layer.
  • a suitable base for example a plastic film provided with a silicone layer.
  • acetone, ethyl acetate or hexane, or solvent mixture ⁇ can be used.
  • the active substance-containing matrix layer is covered with a further film which represents the later back layer of the TTS.
  • the production of the active substance-containing polymer matrix take place starting from a polymer melt, the active substance-containing molten polymer mass being extruded onto a film-shaped carrier in a thin layer.
  • the thickness of the active substance-containing layer is preferably 10 ⁇ m to 2 mm, preferably 50 ⁇ m to 0.5 mm.
  • the skin contact area of a TTS can optionally be approximately 1 to 80 cm 2 , preferably approximately 2 to 20 cm 2 .
  • a TTS can comprise two compartments, each as a reservoir for the phenylcarbama active ingredient
  • the first compartment containing compound (1), e.g. 60 mg
  • the second compartment with scopolamine; e.g. 4 mg
  • the present invention also encompasses TTS designed as bag-shaped systems.
  • the active ingredient (s) is / are contained in a liquid or semi-liquid (e.g. gel-like or viscous) composition which is enclosed in a bag-shaped container.
  • the active ingredient is released via an adhesive-coated membrane in the container, which comes into contact with the skin of the person to be treated.
  • Suitable materials and processes for producing such systems are known in principle to the person skilled in the art.
  • Transdermal systems which are particularly advantageous for the prophylactic administration of compound (1) or active compounds of the formula (2), optionally in combination with at least one further active compound, are disclosed in WO-A-99 34782.
  • the pharmaceutical compositions and components described there are therefore discussed in
  • the active ingredient (s) is / are dissolved in one or more matrix polymers, with hydrophilic polymers being preferred.
  • hydrophilic polymers are preferably selected from the group of polyacrylates and poly ethacrylates; their average molecular weight is preferably in the range from about 50,000 to about 300,000 daltons. In particular, these are polymers with film-forming properties.
  • Preferred acrylate copolymers e.g. B. copolymers of butyl acrylate, ethylhexyl acrylate and vinyl acetate, into consideration. That is also particularly advantageous Use of crosslinked polymers of the type mentioned.
  • particularly suitable polymers are Durotak 87-2353, Durotak 387-2051 and Durotak 387-2052 (available from: National Starch and Chemical Company).
  • the proportion of these polymers can be up to 90% by weight, preferably up to 70% by weight, in each case based on the total weight of the preparation containing the active ingredient.
  • hydrophilic polymers are polyacrylamide and its copolymers, polyvinylpyrrolidones, polyvinyl alcohol and derivatives thereof, vinyl acetate-vinyl alcohol copolymers, ethyl cellulose and other cellulose and starch derivatives.
  • Hydrophilic polyacrylates are most preferred; the polyacrylate may be substituted (e.g. a methacrylate), or some or all of the acid groups may be esterified, e.g. B. with AlkyKCi- to C Q) groups, especially with methyl or ethyl groups.
  • Examples of commercially available polymers of this type are: Plastoid® B (Röhm, Darmstadt); Eudragit® RS 100 and RL 100 (from Röhm); Eudragit® E 100 (from Röhm).
  • hydrophobic polymers can be included, in particular one or more synthetic resins, optionally in combination with modifying substances such as.
  • modifying substances such as.
  • TTS whose active ingredient reservoir contains a pharmaceutical preparation of the following composition are particularly preferred: 20 to 40% by weight (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenyl carbamate (as free base or as a salt, especially as a hydrogen tartrate); 10 to 30% by weight polymethacrylate; 40 to 60% by weight of an acrylate copolymer; 0.05 to
  • the medicaments according to the invention containing compound (1) and / or at least one active substance according to formula (2) are advantageously suitable for the preventive treatment against poisonings caused by cholinesterase inhibitors, in particular toxins of the type mentioned at the outset.
  • cholinesterase inhibitors are generally understood to be compounds which are able to chemically modify the active center of the enzyme, in particular by reaction with hydroxyl groups in the active center. These are primarily organophosphorus compounds, such as organic phosphoric acid esters and organic phosphonic acid esters, and their derivatives in each case.
  • cholinesterase inhibitors from other classes of substance also come into consideration, e.g. B. carbamates, especially those used as crop protection agents (z. B. Carbaryl * 1-naphthyl-N-methy carbamate).
  • the preventive agents according to the invention can be used in agriculture or in horticulture in order to protect employees who have to deal with organophosphorus insecticides or fungicides or can come into contact with them from possible poisoning. These prophylactic drugs are also suitable for protecting people who are used for decommissioning weapons or for decontamination.
  • the invention further includes the use of (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenyl carbamate, or a compound according to formula (2), for the prophylactic treatment of soldiers, police officers and civilians for protection against the named warfare agents or nerve gases.
  • the protective effect brings about a reduction in toxicity and an improvement in the chances of survival after one Toxin exposure. It also increases the chances of success of post-exposure therapy with an atropine-oxime combination.
  • the present invention further relates to methods for the prophylactic treatment or pretreatment of persons in order to protect them from poisoning which are caused by the action of organophosphorus cholinesterase inhibitors.
  • These processes are characterized in that they comprise at least one step in which a medicament which is (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenyl carbamate or / and an active ingredient according to formula (2) contains (in each case optionally in the form of a pharmaceutically acceptable salt), is administered to a person.
  • Drugs containing active ingredients, as described above, are preferably used here.
  • the prophylactic administration of medicaments which contain at least one of the above-mentioned phenylcarbamate active ingredients is preferably carried out at least one day, possibly only at least (2) h before the expected exposure to toxins, provided that it is a predictable event (e.g. handling of insecticides, decontamination work, start of a combat operation).
  • the protective effect can be maintained over a period of several (1 to 7) days to a few weeks by administration of a plurality of successive single doses, preferably by application of depot pharmaceuticals or therapeutic systems (particularly preferably TTS). Depending on the active substance content and the release rate, the application is repeated daily, for example, or at intervals of up to 7 days.
  • At least one drug is used in the prophylactic method administered, which contains (S) -N-ethyl-N-methyl-1-3- [1- (dimethylamino) ethyl] phenyl carbamate or a pharmaceutically acceptable salt of this compound as the sole active ingredient.
  • one or more further active substances from the group of the parasympatholytics are / are additionally administered to the person to be treated, preferably active substance (s) from the group of the tropane alkaloids, scopolamine being particularly preferred becomes.
  • active substance (s) from the group of the tropane alkaloids preferably active substance (s) from the group of the tropane alkaloids, scopolamine being particularly preferred becomes.
  • This combined administration can take place either by application of a medicament which contains the active substances mentioned in combination, or by the simultaneous or successive application of individual medicaments which each contain only one active substance of the active substance combination.
  • a person can be treated prophylactically in such a way that a TTS containing the active ingredient (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenylcarbamate is applied to the skin (e.g. on Upper arm) is applied and during this
  • a second drug which preferably contains scopolamine
  • the treatment can be carried out in such a way that a TTS, which is a combination of at least two active ingredients (e.g. (S) -N-ethyl-N-methyl-1-3- [1- (dimethylamino) ethyl] phenyl carbamate and scopolamine ) contains, is applied to the skin.
  • a TTS which is a combination of at least two active ingredients (e.g. (S) -N-ethyl-N-methyl-1-3- [1- (dimethylamino) ethyl] phenyl carbamate and scopolamine ) contains, is applied to the skin.
  • transdermal or oral administration of (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenylcarbamate with the parenteral administration of at least one further active ingredient, preferably from the group of the parasympatholytics, is also provided , to combine.
  • the protective effect occurs at the earliest after about 4 hours. This delay can occur under certain May be critical, e.g. B. in the event of a terrorist attack, if immediate intervention by soldiers or police is required.
  • the present invention includes a method for prophylactic treatment, the transdermal administration being combined with the oral administration of the above-mentioned active ingredients.
  • a first step (S) N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenyl carbamate (or preferably a combination of this active ingredient and scopolamine) is administered orally to a person in whom a rapid onset of the protective effect is necessary.
  • a short time approximately a short time (approx. 1/2 hour) to produce therapeutic plasma levels that provide protection against warfare agents. This enables the treated person to enter a contaminated environment immediately after an emergency order.
  • a transdermal system (as described above) in order to produce a lasting protective effect (for example up to 24 hours).
  • the TTS can be administered at the same time as the administration of the oral drug; however, it can also be carried out after a delay, preferably within 12 hours after oral administration.
  • This second step can be repeated at certain intervals (e.g. 6 to 24 h) to extend the duration of the protective effect.
  • oral administration is only required to bring about a rapid onset of the protective effect; the maintenance of the protective effect is made possible by administration of one or more transdermal therapeutic systems.
  • This method is particularly simple and safe to use; it enables the rapid build-up of a prophylactic protective effect for those to be protected persons without being exposed to an unacceptable burden of side effects.
  • Preferred oral dosage forms for use in the method described above are tablets and particularly preferably "wafers" (film-like or wafer-shaped dosage forms; as described above).
  • a wafer containing the compound (1) and scopolamine is applied into a person's oral cavity.
  • the active ingredients are released from the wafer and absorbed through the oral mucosa.
  • a therapeutic, prophylactic plasma level that ensures a protective effect is reached quickly (e.g. within 30 min).
  • the prophylactic agents and methods according to the invention are advantageously suitable for pretreating people who are at risk of exposure to toxins.
  • Blood cholinesterase inhibition can be assumed that treatment with 3 mg BID (i.e. twice a day) is sufficient to ensure the required protective effect. This dose is therefore considerably lower than the dose used to treat Alzheimer's patients (12 mg daily; Culter NR et al.: Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol. Scand., 1998, 97 , 244-250).
  • the piglets were exposed to a dose of the nerve agent sarin, which corresponds to twice the LDsQ dose (40 ⁇ g / kg); this was done using an intravenous cannula in the piglet's ear.
  • Untreated piglets died within 4-6 minutes after exposure to combat substances.
  • Treated piglets (approx. 12 kg each) received a 6 mg capsule (S) -N-ethyl-N-methyl-3- [1- (dimethylamino) ethyl] phenyl carbamate hydrogen tartrate; the piglets were also infused with scopolamine 2 h before exposure (0.8 mg / kg / h).
  • blood samples were taken from the subclavian vein to determine scopolamine and to assess cholinesterase inhibition. As can be seen from the table below, all five piglets treated survived.
  • the average recovery time with the piglets standing firmly on their feet, was extremely short (17 min); and this despite the relatively high dose of the nerve agent.
  • ChE cholinesterase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP04702672A 2003-01-17 2004-01-16 Verfahren zur medikamentösen prophylaxe gegen vergiftungen durch cholinesterase-hemmer, sowie hierfür geeignete wirkstoffe und arzneimittel Withdrawn EP1585514A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10301851 2003-01-17
DE10301851A DE10301851A1 (de) 2003-01-17 2003-01-17 Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
PCT/EP2004/000289 WO2004064829A1 (de) 2003-01-17 2004-01-16 Verfahren zur medikamentösen prophylaxe gegen vergiftungen durch cholinesterase-hemmer, sowie hierfür geeignete wirkstoffe und arzneimittel

Publications (1)

Publication Number Publication Date
EP1585514A1 true EP1585514A1 (de) 2005-10-19

Family

ID=32602728

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04702672A Withdrawn EP1585514A1 (de) 2003-01-17 2004-01-16 Verfahren zur medikamentösen prophylaxe gegen vergiftungen durch cholinesterase-hemmer, sowie hierfür geeignete wirkstoffe und arzneimittel

Country Status (9)

Country Link
US (1) US20060183796A1 (enExample)
EP (1) EP1585514A1 (enExample)
JP (1) JP2006516267A (enExample)
KR (1) KR20050104347A (enExample)
CN (1) CN1741800A (enExample)
BR (1) BRPI0406580A (enExample)
DE (1) DE10301851A1 (enExample)
IL (1) IL169687A0 (enExample)
WO (1) WO2004064829A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2936150B1 (fr) * 2008-09-19 2013-09-06 Dermathologiques D Uriage Lab Nouvelles compositions dermatologiques protectrices de la peau et des muqueuses
GB0809905D0 (en) * 2008-06-02 2008-07-09 Secr Defence A Transdermal drug delivery device
CA3193154A1 (en) * 2020-08-31 2022-03-03 Nobelpharma Co., Ltd. Patch for alleviating or treating symptoms of neurodegenerative disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
DK0606366T3 (da) * 1991-09-26 2003-10-06 Us Gov Health & Human Serv Substituerede phenseriner og phenylcarbamater af (-)-eserolin, (-)-N1-noreserolin og (-)-N1-benzylnoreserolin som specifikke inhibitorer af acetylcholinesterase
DE4342174C1 (de) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
US5807671A (en) * 1995-01-09 1998-09-15 Yissum Research Development Company Of Hebrew University Of Jerusalem Method of screening for genetic predisposition to anticholinesterase therapy
US6955819B2 (en) * 1998-09-29 2005-10-18 Zars, Inc. Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances
JP4422342B2 (ja) * 1998-11-27 2010-02-24 ザノヒェミア・ファルマツォイティカ・アー・ゲー せん妄の治療へのコリン作動性中枢神経系エフェクターの使用
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2004064829A1 *

Also Published As

Publication number Publication date
BRPI0406580A (pt) 2005-12-20
KR20050104347A (ko) 2005-11-02
JP2006516267A (ja) 2006-06-29
CN1741800A (zh) 2006-03-01
US20060183796A1 (en) 2006-08-17
WO2004064829A1 (de) 2004-08-05
IL169687A0 (en) 2007-07-04
DE10301851A1 (de) 2004-07-29

Similar Documents

Publication Publication Date Title
EP1178782B1 (de) Transdermales therapeutisches system (tts) tolterodin enthaltend
EP1501499B1 (de) Transepikutane darreichungsform zur behandlung des restless leg syndroms
DE10333393A1 (de) Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
EP0680326B1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
DE102010024105A1 (de) Transdermale Verabreichung von Memantin
DE4342174C1 (de) Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
DE10338174A1 (de) Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE60311449T2 (de) Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen
EP2559427B1 (de) Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)
WO2003092606A2 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
EP1397138A2 (de) Wirkstoff-kombination zur medikamentösen sucht- oder rauschmitteltherapie
EP0732926B1 (de) Pharmazeutische formulierung zur prophylaxe bzw. vorbehandlung einer vergiftung durch phosphororganische cholinesterasehemmer
WO2004064829A1 (de) Verfahren zur medikamentösen prophylaxe gegen vergiftungen durch cholinesterase-hemmer, sowie hierfür geeignete wirkstoffe und arzneimittel
DE19906978B4 (de) Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
EP1850836B1 (de) Medikamentöse kombinationsbehandlung
EP1959938B1 (de) Matrixkontrolliertes transdermales system mit salzen der ace-hemmer-dicarbonsäuren
EP0742716B1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
EP2366388A1 (de) Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin
EP0669826B1 (de) (-)-metrifonat enthaltendes arzneimittel
CN1994307B (zh) 一种预防有机磷酸酯类化合物中毒的复方经皮给药制剂
DE10301930A1 (de) Verfahren zur medikamentösen therapeutischen oder prophylaktischen Behandlung
EP1524982B1 (de) Medikament und verfahren zur verringerung des alkohol-und/oder tabakkonsums
DE102020112143A1 (de) Nicotin - Corona
DE10107828A1 (de) Verwendung von Buprenorphin zur Therapie der Harninkontinenz
DE10317108A1 (de) Transdermal applizierbares Beruhigungs- und Sedierungsmittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050614

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20060301

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110802